| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -97,905 | -61,140 |
| Depreciation expense | 84 | 57 |
| Stock-based compensation expense | 16,815 | 11,021 |
| Accretion of discount on investment securities | 5,308 | 2,997 |
| Amortization of right-of-use operating lease assets | 247 | 175 |
| Gain on investment in former related party | 254 | 27 |
| Receivable from former related party | -807 | -807 |
| Unbilled receivable from former related party | 0 | 0 |
| Accounts receivable, net | 5,000 | 39 |
| Prepaid expenses and other current assets | 1,356 | 1,321 |
| Other assets | -565 | -476 |
| Accounts payable, accrued expenses and operating lease liabilities | 4,593 | 1,589 |
| Deferred revenue | 4,635 | -123 |
| Deferred revenue - former related party | 0 | 0 |
| Net cash used in operating activities | -82,077 | -51,522 |
| Capital expenditures | 75 | 70 |
| Purchases of investment securities | 380,278 | 100,437 |
| Proceeds from maturities of investment securities | 220,317 | 141,746 |
| Net cash used in investing activities | -160,036 | 41,239 |
| Proceeds from public offering | 272,268 | - |
| Payment of issuance costs in connection with public offering | 172 | - |
| Proceeds from exercise of stock options | 2,829 | 599 |
| Proceeds from issuance of common stock under espp | 316 | 129 |
| Proceeds from exercise of pre-funded warrants | 1 | 1 |
| Proceeds from private placement | 0 | 0 |
| Payment of issuance costs in connection with private placement | 0 | 0 |
| Net cash provided by financing activities | 275,242 | 729 |
| Increase/(decrease) in cash, cash equivalents and restricted cash | 33,129 | -9,554 |
| Cash and cash equivalents at beginning of period | 23,022 | - |
| Cash and cash equivalents at end of period | 56,151 | - |
Dianthus Therapeutics, Inc. DE (DNTH)
Dianthus Therapeutics, Inc. DE (DNTH)